local_hospital

Kinder- und Jugendärzte Hürth- Park, Dr. med. Ludwig Stapenhorst

Address
lock Available on a paid plan

Bacterial Infections and Mycoses in Pediatric Vaccination Research

At Kinder- und Jugendärzte Hürth- Park, Dr. med. Ludwig Stapenhorst, clinical research in Bacterial Infections and Mycoses focuses on preventing serious childhood infections through vaccination. The studies center on common and potentially severe diseases such as pneumococcal and meningococcal immunization, with the goal of evaluating how well new vaccine options protect infants and young children.

  • Testing a newer pneumococcal vaccine for its ability to generate strong immune protection against shared and additional serotypes
  • Assessing whether an investigational meningococcal vaccine can provide safe and effective immune responses in children, toddlers, and infants

The pediatric clinic in Hürth is contributing to research that aims to improve infection prevention in early life by comparing immune responses and safety profiles across vaccine candidates.

Site Overview

assignment
1
connected trial
corporate_fare
1
sponsor
science
32
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
1
Total trials linked
Low Activity
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 1 therapeutic areas and 15 of 32 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
0
Sponsors (total)
1
Active sponsors
0

Sponsor Network

Top 10 by active trials.

No sponsors linked to active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 2 161 other sites in Germany

description
Trial volume
1
Outperforms 2% of sites
public
Therapeutic diversity
1areas
Outperforms 2% of sites
groups
Sponsor diversity
1sponsors
Outperforms 2% of sites

Therapeutic Area Benchmark — Germany

Select a therapeutic area to compare against other sites in Germany.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Germany

Market Share

Country: Germany

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Kinder- und Jugendärzte Hürth- Park, Dr. med. Ludwig Stapenhorst

Trial Sponsor Phase Status Start Date End Date
Evaluation of Immunogenicity and Safety of Pentavalent Meningococcal ABCYW Vaccine in Pediatric Populations Compared to Licensed Meningococcal VaccinesSanofi Pasteur Inc.Phase IINot RecruitingMar 2025

IMP list

lock Showing 1 of 32 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE)1Unknown2025-03-102025-03-10

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.